Kyntra Bio (KYNB) EV to EBITDA (2014 - 2026)

Kyntra Bio has disclosed EV to EBITDA across 13 years of filings, most recently posting 2.23 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 278.8% year-over-year to 2.23; the TTM figure through Jun 2026 stood at 0.78 (up 523.86% YoY), while the FY2025 annual figure was 0.7, up 215.28% from the prior year.
• EV to EBITDA came in at 2.23 for Q2 2026 at Kyntra Bio, down from 2.77 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 12.82 in Q3 2025 to a low of 19.28 in Q1 2023.
• Average EV to EBITDA over 5 years is 1.96, with a median of 0.83 recorded in 2024.
• The largest YoY upside for EV to EBITDA was 782.72% in 2025 against a maximum downside of 212.53% in 2025.
• Over 5 years, EV to EBITDA stood at 16.42 in 2022, then jumped by 108.1% to 1.33 in 2023, then soared by 250.04% to 4.66 in 2024, then plunged by 49.22% to 2.37 in 2025, then fell by 5.55% to 2.23 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 2.23 in Q2 2026, 2.77 in Q1 2026, and 2.37 in Q4 2025.